

# Comparing the Availability of New Medicines in the United States and Other Countries

	New Medicines Available	Average Delay in Availability of New Medicines
Greece	16%	31 months
Ireland	41%	20 months
Belgium	44%	22 months
Czech Republic	44%	24 months
Canada	46%	15 months
France	50%	18 months
Finland	51%	16 months
Italy	51%	20 months
Japan	51%	16 months
Netherlands	53%	7 months
Denmark	54%	12 months
Austria	58%	11 months
United Kingdom	59%	18 months
Germany	63%	10 months
United States	87%	0-3 months

Source: PhRMA analysis of IQVIA Analytics Link and FDA, EMA and PMDA data. June 2020. Note: New Active Substances (NASs) approved by the FDA, EMA and/or PMDA and first launched in any country between January 2011 and December 2019. Average delay represents the time in months since global first launch among NASs that have launched in a given country. IQVIA reports only the retail channel for Greece. Updated July 2020

# Comparing the Availability of New Cancer Medicines in the United States and Other Countries

	New Cancer Medicines Available	Average Delay in Availability of Cancer Medicines
Greece	16%	41 months
Ireland	53%	23 months
Belgium	55%	25 months
Czech Republic	55%	24 months
Italy	58%	21 months
Japan	58%	23 months
Canada	59%	14 months
Finland	61%	14 months
Netherlands	63%	9 months
Denmark	64%	11 months
France	67%	16 months
Austria	68%	11 months
United Kingdom	70%	12 months
Germany	73%	11 months
United States	96%	0-2 months

Source: PhRMA analysis of IQVIA Analytics Link and FDA, EMA and PMDA data. June 2020. Note: New Active Substances (NASs) approved by the FDA, EMA and/or PMDA and first launched in any country between January 2011 and December 2019. Average delay represents the time in months since global first launch among NASs that have launched in a given country. IQVIA reports only the retail channel for Greece. Updated July 2020